rhGH

ApprovedSmall molecule

XXiamen Amoytop Biotech Co., Ltd.

rhGH is one of 88 small molecule programs targeting Short stature. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Short StatureActive, not recruiting

Growth Hormone DeficiencyActive, not recruiting

Short Bowel SyndromeActive, not recruiting

GrowthActive, not recruiting

Short StaturePhase 2

Active, not recruiting

Growth Hormone DeficiencyPhase 1/Phase 2

Active, not recruiting

Short Bowel SyndromePhase 3

Active, not recruiting

GrowthApproved

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

rhGH

XXiamen Amoytop Biotech Co., Ltd.

Approved

3 2

Genotropin

EMD Serono

Preclinical

35 3

Lovenox

Sanofi

Preclinical

2 4

Lenvima

Eisai

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Aricept

Eisai

Preclinical

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Somavaratan

Glucophage

2 10

EGRIFTA WR

TTheratechnologies

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1/2Not yet recruiting

Growth Hormone Deficiency

NCT07264595

Clinical

Trials by Indication[1]

Growth3 trials

Mechanism of Growth Hormone Effects on Adipose Tissue

Completed·PPennington Biomedical Research Center·Phase 4·NCT00453557·30 enrolled

Long-Acting Growth Hormone in Children Compared to Daily rhGH

Completed·VVersartis Inc.·Phase 3·NCT02339090·138 enrolled

Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT00597480·10 enrolled

Short Bowel Syndrome1 trial

Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome

Completed·HHospices Civils de Lyon·Phase 3·NCT00169637·14 enrolled

Short stature1 trial

A Trial of YPEG-rhGH in Children With Short Stature

Completed·XXiamen Amoytop Biotech Co., Ltd.·Phase 2·NCT05838885·78 enrolled

GH Deficiency1 trial

Vesiculogenesis in Children With GH Deficiency (VESCIGHTP)

Active, not recruiting·IIstituto Auxologico Italiano··NCT05759624·10 enrolled

Growth Hormone Deficiency1 trial

A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)

Not yet recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1/2·NCT07264595·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for rhGH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rhGH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rhGH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiamen Amoytop Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: XXiamen Amoytop Biotech Co., Ltd.

rhGH

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Growth3 trials

Short Bowel Syndrome1 trial

Short stature1 trial

GH Deficiency1 trial

Growth Hormone Deficiency1 trial

References

Drug Info

Quick Facts

Related News